Abstract | INTRODUCTION: AREAS COVERED: Evaluation of the patent activity over the last decade (2002 - 2012) illustrates many potent and selective modulators of the distinct prostanoid receptors and some novel methods for their use besides the classical indications. By now, some prostaglandin receptor antagonists already have reached clinical development. EXPERT OPINION: Though the structural diversity of compounds targeting prostanoid receptors is not really large, several highly potent agents with favorable properties have been developed. The clinical potential of FP, IP, TP and DP modulators remains to be investigated, while first very promising clinical results are available as far as CRTH2 is concerned.
|
Authors | Christina Lamers, Daniel Flesch, Manfred Schubert-Zsilavecz, Daniel Merk |
Journal | Expert opinion on therapeutic patents
(Expert Opin Ther Pat)
Vol. 23
Issue 1
Pg. 47-77
(Jan 2013)
ISSN: 1744-7674 [Electronic] England |
PMID | 23151189
(Publication Type: Journal Article, Review)
|
Chemical References |
- Prostaglandins
- Receptors, Prostaglandin
|
Topics |
- Animals
- Drug Design
- Humans
- Molecular Targeted Therapy
- Patents as Topic
- Prostaglandins
(metabolism)
- Receptors, Prostaglandin
(drug effects, metabolism)
|